Teza Capital Management LLC Makes New Investment in Zoetis Inc. $ZTS

Key Points

• Teza Capital Management LLC acquired a new stake in Zoetis Inc., purchasing 2,776 shares valued at approximately $457,000 during the first quarter.
• Several institutional investors, including Saudi Central Bank and Cornerstone Planning Group LLC, have also increased their holdings in Zoetis, indicating strong institutional interest, with 92.80% of the stock currently owned by institutional investors.
• After recent analyst reports, Zoetis has seen target price changes, with some firms lowering their ratings, yet it maintains a consensus rating of "Moderate Buy" and an average price target of $202.43.

Teza Capital Management LLC acquired a new position in Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,776 shares of the company's stock, valued at approximately $457,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Portside Wealth Group LLC grew its holdings in Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. grew its holdings in Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after purchasing an additional 198,089 shares during the period. Flagship Harbor Advisors LLC grew its holdings in Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after purchasing an additional 1,760 shares during the period. Horizon Financial Services LLC bought a new stake in Zoetis during the first quarter valued at about $380,000. Finally, Sage Rhino Capital LLC grew its holdings in Zoetis by 117.6% during the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after purchasing an additional 3,791 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

Shares of NYSE:ZTS traded up $1.24 during midday trading on Thursday, reaching $150.66. 3,193,921 shares of the company were exchanged, compared to its average volume of 3,037,636. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The business's fifty day moving average is $152.70 and its two-hundred day moving average is $157.56. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The stock has a market cap of $66.77 billion, a PE ratio of 25.93, a price-to-earnings-growth ratio of 2.40 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the business earned $1.56 earnings per share. Zoetis's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on ZTS shares. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Argus reaffirmed a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.